The concentration of α1-microglobulin (α1-m) in sera and cerebrospinal fluids (CSF) was measured in 121 patients with various neurological disorders. Using single radial immunodiffusion, its serum level was determined. No significant difference was found between the patients (29.1 ± 4.3 mg/1; mean ± 1 SD) and normal control group (23.7 ± 4.6 mg/1). The level of CSF (α1-m was determined by the radioimmunoassay of solid antibody system. Its CSF level in the control group was 34.8 ± 16.0µg/l, while it was significantly increased in the patients with viral meningitis (p < 0.01) and cerebral infarct (p < 0.05). The level was also elevated in some cases of brain tumor, bacterial meningitis, cerebral hemorrhage, cervical spondylosis, and acute lymphocytic leukemia. There was a positive correlation between α1m and albumin levels in CSF. The analysis by CSF/serum albumin ratio and α1-m ratio suggested that the increase of α1-m in CSF could be explained mainly by an increase in permeability of the serum α1-m through damaged blood brain barrier under these pathological conditions. Its local production within the central nervous system, however, could not be ruled out in these disorders.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.